Skip to main content
Clinical Trials/NCT04993482
NCT04993482
Recruiting
Not Applicable

24-hour Movement Behaviors Among Type 2 Diabetes Mellitus Patients

University Hospital, Ghent1 site in 1 country248 target enrollmentAugust 29, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus, Type 2
Sponsor
University Hospital, Ghent
Enrollment
248
Locations
1
Primary Endpoint
Change in 24-hour movement composition from baseline over one year and two-year follow-up
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

A healthy lifestyle has proved beneficial health effects in managing type 2 diabetes mellitus (T2DM). Important lifestyle behaviors, i.e. sleep, sedentary time (SB), and physical activity (PA) subdivided into light physical activity (LPA) and moderate to vigorous physical activity (MVPA), have shown an impact on T2DM disease-specific characteristics (e.g. glycemic control). However, these behaviors have often been investigated separately. Therefore, a recent shift in research emphasizes the importance of considering these behaviors as part of a 24-hour day.

Since T2DM patients can benefit from an optimal 24-hour composition as part of a healthy lifestyle, it may be interesting to investigate the 24-hour movement composition among these T2DM patients over time. Moreover, exploring associations with different personal determinants, environmental determinants, and cardiometabolic markers will provide meaningful insights in developing recommendations and creating an intervention.

Detailed Description

The present study aims (1) to conduct a longitudinal observational study over two years to explore 24-hour movement behavior composition patterns among T2DM patients in comparison with a healthy control group and (2) to examine associations between these movement behaviors and personal and environmental determinants, and cardiometabolic markers. This study's primary endpoint is to develop insights into the 24-hour movement composition combined with T2DM patients' characteristics, determinants, and health profile to set the groundwork with the aim to develop, implement and evaluate an intervention in a future randomized controlled trial

Registry
clinicaltrials.gov
Start Date
August 29, 2021
End Date
December 1, 2026
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change in 24-hour movement composition from baseline over one year and two-year follow-up

Time Frame: The same primary outcome will be collected after two years

During their visit to Ghent University hospital, participants will receive a wGT3X-BT ActiGraph accelerometer that will objectively measure their 24-hour movement behaviors (PA, SB, and sleep). The participants will wear the accelerometer for seven consecutive days. Additionally, this accelerometer data will be supplemented with a diary to validate sleep time and (non)wear time. Furthermore, the individuals will subjectively report on their PA, SB, and sleep (duration and quality) through an online questionnaire based on international standardized PA (IPAQ), SB (SIT-Q-7d), and sleep questionnaires (Munich Chronotype questionnaire, Pittsburg sleep quality index, and Sleep Hygiene Index) (IPAQ, Sit-7Q, Munich Chronotype questionnaire, and Pittsburg sleep quality index, Sleep Hygiene Index). By collecting the same variable on three timepoints, it is possible to determine if this outcome will change or remain stable over time.

Secondary Outcomes

  • Change in Homeostatic Model Assessment (HOMA) from baseline to two-year follow-up(The same secondary outcome will be collected after two years)
  • Change in waist circumference from baseline to one and two-year follow-up(The same secondary outcome will be collected after two years)
  • Change in HbA1c from baseline to two-year follow-up(The same secondary outcome will be collected after two years)
  • Change in cholesterol (total, HDL, LDL) from baseline to two-year follow-up(The same secondary outcome will be collected after two years)
  • Change in triglycerides from baseline to two-year follow-up(The same secondary outcome will be collected after two years)
  • Change in Body Mass Index (BMI) from baseline to one and two-year follow-up(The same secondary outcome will be collected after two years)
  • Change in insulin from baseline to two-year follow-up(The same secondary outcome will be collected after two years)
  • Change in systolic and diastolic blood pressure from baseline to one and two-year follow-up(The same secondary outcome will be collected after two years)
  • Change in Advanced Glycation Endproducts from baseline to one and two-year follow-up(The same secondary outcome will be collected after two years)
  • Change in glucose from baseline to two-year follow-up(The same secondary outcome will be collected after two years)

Study Sites (1)

Loading locations...

Similar Trials